Table 1.
Clinical information on the patients in the four eligible trials
| Study | Tumor stage | All patients (male patients) | CIK regimen | DC regimen | CIK cell culture conditions | DC culture conditions |
|---|---|---|---|---|---|---|
| Gao et al8 | I–IV | 26 (U) | 5.9±2.2×109 | 1.9±7.9×107 | IL-2, IFN-γ, CD3 | Tumor lysate IL-4, GM-CSF |
| Lin et al17 | IV | 255 (140) | 1.0×109 | 1.0×107 | IL-2, IFN-γ, CD3 | Tumor lysate IL-4, GM-CSF TNF |
| Niu et al25 | I–IV | 239 (113) | 1.0×109 | 1.0×107 | IL-2, IFN-γ, CD3 | Tumor lysate IL-4, GM-CSF TNF |
| Zhu et al54 | IV | 351 (229) | 1.0×109 | 1.0×107 | IL-2, IFN-γ, CD3 | Tumor lysate IL-4, GM-CSF TNF |
| Study | 0.5-year OS (%) of DC-CIK/chemo (chemo) |
1-year OS (%) of DC-CIK/chemo (chemo) |
1.5-year OS (%) of DC-CIK/chemo (chemo) |
2-year OS (%) of DC-CIK/chemo (chemo) |
0.5-year DFS (%) of DC-CIK/chemo (chemo) |
1-year DFS (%) of DC-CIK/chemo (chemo) |
| Gao et al8 | 100 (84.6) | 100 (76.9) | 100 (53.8) | 92.3 (41.2) | 100 (76.9) | 100 (69.2) |
| Lin et al17 | 100 (90.1) | 74.6 (34.7) | 24.6 (9.1) | 22.4(7.4) | — | — |
| Niu et al25 | 76.5 (45.5) | 47.1 (18.2) | — | — | 52.7 (34.6) | 21.6 (9.2) |
| Zhu et al54 | 90 (83.7) | 81 (69.7) | 72 (57.8) | — | — | — |
Abbreviations: CIK, cytokine-induced killer; DC, dendritic cell; U, unknown; GM-CSF, granulocyte macrophage colony-stimulating factor; TNF, tumor necrosis factor; OS, overall survival; DC-CIK/chemo, DC vaccine and CIK cell immunotherapy combined with chemotherapy; Chemo, chemotherapy alone; DFS, disease-free survival.